Market Research Reports, Inc. has announced the addition of “Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis” research report to their offering. See more at- http://mrr.cm/o6z

1. www.MarketResearchReports.com
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

2. www.MarketResearchReports.com
Introduction to Report
 Launch Date: November 30, 2015
 Number of Pages: 470
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 2,500
Price For Site User License: USD 3,000
Price For Global User License: USD 10,000
Delivery Time: Within 24 Hours (During Working Days)

3. www.MarketResearchReports.com
About the Report
Antibody-Drug Conjugates 2016: Perspectives &
Opportunities - a Pipeline, Technology, Stakeholder &
Business Analysis is based on the analysis of more than 90
companies, more than 100 ADC drug profiles and more
than 26 ADC technologies and components.
Sources of information are provided by 274 scientific
references and numerous non-scientific references, e.g.
press releases, stock exchange disclosures, presentations,
annual reports, fact sheets (with hyperlinks leading to
source of information).

4. www.MarketResearchReports.com
Key Highlights:
The report also describes and analyzes business deals in
the ADC field, e.g. collaboration and license agreements,
mergers and acquisitions, financial transactions
(divestments, public offerings, private equity and venture
capital fund-raising).
For the first time in 2015, combined sales of the
approved and marketed ADC products Adcetris and
Kadcyla will surpass the sales limit of US$ 1 billion.
The pipeline of ADCs and immunoconjugates in
advanced clinical development gives the chance of
approval of further ADCs in the near- and mid-term
future.

5. www.MarketResearchReports.com
Key Highlights Continues…
The clinical attrition rate of ADCs is lower, i.e. better,
than that of conventional, naked antibodies in oncology.
The availability of next generation ADC technologies
allows to select case by case the appropriate linker and
payload. Site-specific conjugation technologies with and
without engineering of the antibody generate
homogenous products.
Novel payloads provide the basis for enhanced
antitumor activity. Prodrug concepts and polymeric
carrier systems may not only contribute to a higher
therapeutic index, but also boost efficacy by targeted
delivery of a higher number of payloads than in
conventional ADCs.

6. www.MarketResearchReports.com
Key Highlights Continues…
Competition by ADCs directed against the same target is
relatively low, except for clinically and commercially
validated Her2 which is ideal to validate new
technologies.
However, targets are still a bottleneck with the attractive
consequence that companies with successful target
identification capabilities are highly rewarded by
investors and business partners.
Although the initial enthusiasm about antibody-drug
conjugates has made room for a more realistic
understanding, the prospects for success of ADC drug
candidates remain good and are based on a well-filled
pipeline, increasing adoption of next generation ADC
technologies, lessons learned from failures, a balanced
mixture of stakeholders and a variety of options for
funding of ADC developments.

7. www.MarketResearchReports.com
Coverage of this ADC report:
Next-to-market ADCs
ADC Drug Profiles: clinical, pre-IND, preclinical
Target Competition by ADCs
ADC Development Failures
Conventional & Emerging ADC Technologies
Polymeric ADC Carriers
Novel ADC Payloads & Linkers
Site-specific ADC Conjugation Technologies
Major Pharma & Biotech Companies with ADC Programs
Small and Medium Biopharmaceutical Companies with
ADC Programs
Integrated ADC Technology & Pipeline Companies

8. www.MarketResearchReports.com
Coverage of this ADC report:
Companies with Linker, Payload, Carrier and Conjugation
Technologies
Commercial Opportunities and Perspectives with ADCs
Commericalization of Approved ADCs
Fund-Raising for ADC Companies
Pharma-Biotech & Biotech-Biotech Collaboration &
Licensing Agreements

9. www.MarketResearchReports.com
Report Coverage:
1. Executive Summary
2. ADC Pipeline Analysis
3. ADC Technology Analysis
4. ADC Stakeholder Analysis
5. ADC Business Analysis
6. ADC Drug Profiles
7. ADC Company Profiles
8. References
9. ADDENDUM
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

10. www.MarketResearchReports.com
Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter
at:
http://www.marketresearchreports.com/subscribe-to-
newsletter

11. www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/o6z
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)